FindTrial
Sign In

Efficiency of enalapril in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy

Efficiency of enalapril in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy compared with control group in Toba clinic in 2013-2014

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013042213090N1
Enrollment
Unknown
Registered
2013-06-03
Start date
2013-05-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer. Neoplasms

Interventions

Treatment - Drugs
Control group receive chemotherapy drug alone.
In casel group,atleast 24 hours before chemotherapy,enalapril 5-10mg BID is initiatatad and continued till termination of chemotherapy.
Intervention 1: In casel group,atleast 24 hours before chemotherapy,enalapril 5-10mg BID is initiatatad and continued till termination of chemotherapy. Intervention 2: Control group receive chemother

Sponsors

Vice chancellor for research, Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged between 18-70 years old; new diagnosed cancer patients that should be underwent antracyclin therapy. Exclusion criteria: history of myocardial infarction or coronary artery disease; LVEF<50%; significant valvular heart disease; history of congestive heart failure; renal failure with glomerular filteration rate of less than 30ml/h; history of allergy to ACEI and systolic blood pressure less than 90 mmHg.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cardiomyopathy. Timepoint: Before treatment,6 months later. Method of measurement: Echocardiography.—

Secondary

MeasureTime frame
Level of cardiac Troponin-I. Timepoint: One month after treatment. Method of measurement: Venopuncture.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Nabati

Mazandaran University of Medical Sciences

Dr.mr.nabati@gmail.com+98 15 1222 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026